CN 128

Drug Profile

CN 128

Alternative Names: CN128

Latest Information Update: 08 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hangzhou Zede Pharmaceutical Technology
  • Class Antianaemics; Heterocyclic acids; Pyridones; Small molecules; Thiazoles
  • Mechanism of Action Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Iron overload

Most Recent Events

  • 08 Nov 2016 Hangzhou Zede Pharmaceutical Technology plans a phase I trial of CN 128 in healthy volunteers in Thailand (TCTR20161110001)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top